bioAffinity Technologies (BIAF) Invested Capital (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of Invested Capital data on file, last reported at $4.3 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $4.3 million, up 95.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.3 million (up 95.35% YoY), and the FY2025 annual result was $7.9 million, up 130.98% from the prior year.
• Invested Capital declined to $4.3 million in Q1 2026 per BIAF's latest filing, from $7.9 million in the prior quarter.
• Over five years, Invested Capital peaked at $22.0 million in Q3 2022 and troughed at -$16.8 million in Q2 2022.
• A 5-year average of $4.2 million and a median of $6.1 million in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2025: Invested Capital surged 261.16% in 2022, then sank 143.82% in 2025.
• A 5-year view of Invested Capital shows it stood at $11.3 million in 2022, then slumped by 46.38% to $6.1 million in 2023, then plunged by 43.17% to $3.4 million in 2024, then jumped by 130.98% to $7.9 million in 2025, then plunged by 46.46% to $4.3 million in 2026.
• Business Quant data shows BIAF's Invested Capital at $4.3 million in Q1 2026, $7.9 million in Q4 2025, and $9.0 million in Q3 2025.